Subtopic Deep Dive
Molecular Genetics of Vascular Sarcomas
Research Guide
What is Molecular Genetics of Vascular Sarcomas?
Molecular genetics of vascular sarcomas studies recurrent genetic alterations like MYC amplifications, FLT4 gains, KDR mutations, and p53/PIK3CA pathway changes in angiosarcomas using next-generation sequencing and comparative genomic hybridization.
Research identifies MYC amplification as a hallmark of radiation-induced angiosarcomas, distinguishing them from atypical vascular lesions (Guo et al., 2010; 339 citations; Manner et al., 2009; 313 citations). Multiomic analyses reveal distinct subtypes with actionable mutations in PIK3CA, TP53, and PLCG1 (Chan et al., 2020; 99 citations; Wang et al., 2017; 83 citations). Over 20 key papers from 2009-2021 document genotype-phenotype correlations in these rare vascular tumors.
Why It Matters
MYC amplification guides risk stratification in post-radiation breast angiosarcomas, enabling targeted surveillance (Mentzel et al., 2011; 259 citations; D’Angelo et al., 2013; 72 citations). p53 and PIK3CA/AKT/mTOR alterations suggest mTOR inhibitors for therapy-resistant cases (Italiano et al., 2012; 121 citations). Multiomic subtyping supports immunotherapy trials like ipilimumab/nivolumab for metastatic angiosarcoma (Wagner et al., 2021; 146 citations), improving precision medicine outcomes in this aggressive sarcoma.
Key Research Challenges
Heterogeneity in Mutation Profiles
Angiosarcomas show site-specific genetics, with MYC/FLT4 amplifications dominant in radiation-induced cases but absent in primary tumors (Guo et al., 2010; Manner et al., 2009). Distinguishing drivers from passengers requires large cohorts. NGS data integration across subtypes remains inconsistent (Chan et al., 2020).
Limited Tissue Availability
Rare incidence limits sample sizes for genomic profiling, hindering statistical power (Italiano et al., 2012). Canine models reveal shared mutations like PIK3CA/TP53 but translation to humans needs validation (Wang et al., 2017). Archival samples often yield degraded DNA.
Translating Genomics to Therapy
Actionable mutations like KDR/PIK3CA exist, but clinical trials show variable responses (Wagner et al., 2021). Correlating miR-17-92 expression with MYC status lacks therapeutic targets (Italiano et al., 2012b; 103 citations). Resistance mechanisms post-immunotherapy require study.
Essential Papers
Consistent <i>MYC</i> and <i>FLT4</i> gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions
Tianhua Guo, Lei Zhang, Ning‐En Chang et al. · 2010 · Genes Chromosomes and Cancer · 339 citations
Abstract Angiosarcoma (AS) is a distinct group of sarcomas characterized by upregulation of vascular‐specific receptor tyrosine kinases, including TIE1 , KDR , TEK , and FLT1. In keeping with the c...
MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema
Johanna Manner, Bernhard Radlwimmer, Peter Hohenberger et al. · 2009 · American Journal Of Pathology · 313 citations
Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases
Thomas Mentzel, Hans‐Ulrich Schildhaus, Gabriele Palmedo et al. · 2011 · Modern Pathology · 259 citations
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J. Wagner, Megan Othus, Sandip Pravin Patel et al. · 2021 · Journal for ImmunoTherapy of Cancer · 146 citations
Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies hav...
A review of soft-tissue sarcomas: translation of biological advances into treatment measures
Ngoc T. Hoang, Luis A. Acevedo, Michael J. Mann et al. · 2018 · Cancer Management and Research · 137 citations
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an overall incidence of about five per 100,000 per year. While this diverse family of malignancies comprises ...
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas
Antoîne Italiano, Chun‐Liang Chen, Rachael Thomas et al. · 2012 · Cancer · 121 citations
Abstract BACKGROUND: The p53 and phosphoinositide‐3‐kinase, catalytic, alpha polypeptide/v‐akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PIK3CA/AKT/mTOR) pathways frequ...
The miR‐17‐92 cluster and its target <i>THBS1</i> are differentially expressed in angiosarcomas dependent on <i>MYC</i> amplification
Antoîne Italiano, Rachael Thomas, Matthew Breen et al. · 2012 · Genes Chromosomes and Cancer · 103 citations
Abstract Angiosarcomas (ASs) represent a heterogeneous group of malignant vascular tumors that may occur spontaneously as primary tumors or secondarily after radiation therapy or in the context of ...
Reading Guide
Foundational Papers
Start with Guo et al. (2010; 339 citations) for MYC/FLT4 discovery in radiation angiosarcoma, Manner et al. (2009; 313 citations) for lymphedema context, and Mentzel et al. (2011; 259 citations) to distinguish from atypical lesions—these establish core amplification patterns.
Recent Advances
Study Chan et al. (2020; 99 citations) for multiomic subtypes across 68 cases, Wagner et al. (2021; 146 citations) for immunotherapy outcomes, and Wang et al. (2017; 83 citations) for cross-species actionable mutations.
Core Methods
Core techniques include NGS for mutation profiling, CGH for amplifications, qPCR/FISH for MYC/FLT4 validation, and NanoString for immunoprofiling (Guo et al., 2010; Chan et al., 2020).
How PapersFlow Helps You Research Molecular Genetics of Vascular Sarcomas
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve Guo et al. (2010) on MYC/FLT4 amplifications, then citationGraph maps 339 citing papers linking to radiation-induced subtypes, while findSimilarPapers uncovers Manner et al. (2009) for lymphedema-associated cases.
Analyze & Verify
Analysis Agent employs readPaperContent on Chan et al. (2020) multiomic data, runPythonAnalysis to plot mutation frequencies across 68 angiosarcomas using pandas/NumPy, and verifyResponse with CoVe for GRADE-assessed evidence on PIK3CA prevalence, plus statistical verification of subtype survival correlations.
Synthesize & Write
Synthesis Agent detects gaps in MYC-targeted therapies via contradiction flagging across Italiano et al. (2012) papers, while Writing Agent uses latexEditText, latexSyncCitations for Guo/Mentzel manuscripts, latexCompile for figures, and exportMermaid to diagram p53-PIK3CA pathway alterations.
Use Cases
"Extract mutation frequencies from canine hemangiosarcoma NGS data in Wang et al. 2017"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas to tabulate PIK3CA/TP53 rates) → CSV export of 50%+ prevalence stats for human translation.
"Draft LaTeX review section on MYC amplification in radiation angiosarcomas"
Synthesis Agent → gap detection → Writing Agent → latexEditText (insert Guo 2010 summary) → latexSyncCitations (add 339-citation ref) → latexCompile → PDF with pathway diagram.
"Find code for analyzing angiosarcoma multiomic subtypes"
Research Agent → paperExtractUrls (Chan 2020) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs R scripts for NanoString immuno-profiling from 68-patient dataset.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Guo et al. (2010), generating structured report on MYC subtypes with GRADE tables. DeepScan applies 7-step CoVe to verify PIK3CA mutations across Italiano papers, checkpointing phenotype correlations. Theorizer hypothesizes FLT4-targeted therapies from miR-17-92 data (Italiano et al., 2012b).
Frequently Asked Questions
What defines molecular genetics of vascular sarcomas?
It examines recurrent alterations like MYC amplification, FLT4 gains, KDR mutations, and p53/PIK3CA changes in angiosarcomas via NGS and CGH (Guo et al., 2010; Chan et al., 2020).
What are key methods used?
Next-generation sequencing, comparative genomic hybridization, and multiomic profiling including NanoString immuno-oncology panels identify drivers like MYC in radiation cases (Manner et al., 2009; Chan et al., 2020).
What are the most cited papers?
Guo et al. (2010; 339 citations) on MYC/FLT4 in radiation angiosarcoma; Manner et al. (2009; 313 citations) on lymphedema cases; Mentzel et al. (2011; 259 citations) on breast post-radiation MYC.
What open problems exist?
Validating canine mutations (PIK3CA/TP53) in human trials, overcoming sample scarcity for rare primaries, and developing therapies beyond immunotherapy for MYC-high subtypes (Wang et al., 2017; Wagner et al., 2021).
Research Vascular Tumors and Angiosarcomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Molecular Genetics of Vascular Sarcomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Tumors and Angiosarcomas Research Guide